why choose us

First received: September 26, 2023

Clinical Trial: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Study Status: Completed

Recruit Status: RECRUITING

Condition: Crohn's Disease

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn&

Brief Summary: Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels.It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss.This study will assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely active CD in adult participants.Risankizumab is an approved drug for adults with CD.This study comprises of a Period A and…

Read more